BRPI1009022A2 - "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit" - Google Patents

"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"

Info

Publication number: BRPI1009022A2
Authority: BR; Brazil
Prior art keywords: compound; pharmaceutical composition; disorder; kit; disease
Prior art date: 2009-05-27

Application number

BRPI1009022A

Other languages

English (en)

Inventor

Brian Safina

Bryan Chan

Daniel P Sutherlin

David Michael Goldstein

Eileen Mary Seward

Georgette Castanedo

Matthew C Lucas

Pascal Pierre Alexandre Savy

Rama K Kondru

Stephen Price

Wylie Solang Palmer

Zachary Kevin Sweeney

Original Assignee

Hoffmann La Roche

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-05-27

Filing date

2010-05-26

Publication date

2016-03-08

2010-05-26 Application filed by Hoffmann La Roche, Genentech Inc filed Critical Hoffmann La Roche

2016-03-08 Publication of BRPI1009022A2 publication Critical patent/BRPI1009022A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Communicable Diseases (AREA)
Transplantation (AREA)
Oncology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Endocrinology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI1009022A 2009-05-27 2010-05-26 "composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit" BRPI1009022A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US18145209P	2009-05-27	2009-05-27
US28760709P	2009-12-17	2009-12-17
PCT/US2010/036199 WO2010138589A1 (en)	2009-05-27	2010-05-26	Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Publications (1)

Publication Number	Publication Date
BRPI1009022A2 true BRPI1009022A2 (pt)	2016-03-08

Family

ID=42370969

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1009022A BRPI1009022A2 (pt)	2009-05-27	2010-05-26	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"

Country Status (12)

Country	Link
US (2)	US8173650B2 (pt)
EP (1)	EP2435438A1 (pt)
JP (1)	JP5781066B2 (pt)
KR (1)	KR20130026364A (pt)
CN (1)	CN102459272B (pt)
AU (1)	AU2010254161A1 (pt)
BR (1)	BRPI1009022A2 (pt)
CA (1)	CA2761445A1 (pt)
IL (1)	IL215580A0 (pt)
MX (1)	MX2011012520A (pt)
SG (1)	SG175708A1 (pt)
WO (1)	WO2010138589A1 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0721095D0 (en) *	2007-10-26	2007-12-05	Piramed Ltd	Pharmaceutical compounds
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8158624B2 (en) *	2008-05-30	2012-04-17	Genetech, Inc.	Purine PI3K inhibitor compounds and methods of use
US8569296B2 (en) *	2009-09-29	2013-10-29	Xcovery Holding Company, Llc	PI3K (delta) selective inhibitors
US8604032B2 (en)	2010-05-21	2013-12-10	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
GB201012889D0 (en) *	2010-08-02	2010-09-15	Univ Leuven Kath	Antiviral activity of novel bicyclic heterocycles
US8293736B2 (en)	2010-07-14	2012-10-23	F. Hoffmann La Roche Ag	Purine compounds selective for PI3K P110 delta, and methods of use
EP2637669A4 (en)	2010-11-10	2014-04-02	Infinity Pharmaceuticals Inc	Heterocyclic compounds and their use
BR112013014914B8 (pt)	2010-12-16	2020-08-04	Hoffmann La Roche	composto, composição farmacêutica e uso de um composto
KR20180080358A (ko)	2011-01-10	2018-07-11	인피니티 파마슈티칼스, 인코포레이티드	이소퀴놀린온 및 이의 고체 형태의 제조 방법
CA2825028A1 (en) *	2011-02-09	2012-08-16	F. Hoffman-La Roche Ag	Heterocyclic compounds as pi3 kinase inhibitors
CA2831582C (en)	2011-03-28	2019-01-08	Mei Pharma, Inc.	(alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
WO2013012918A1 (en)	2011-07-19	2013-01-24	Infinity Pharmaceuticals Inc.	Heterocyclic compounds and uses thereof
US8969363B2 (en)	2011-07-19	2015-03-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN103998442B (zh)	2011-08-29	2016-09-14	无限药品股份有限公司	杂环化合物及其用途
KR101273566B1 (ko)	2011-09-05	2013-06-11	한국과학기술연구원	신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물
PT2771342T (pt)	2011-10-28	2016-08-17	Novartis Ag	Derivados de purina e o seu uso no tratamento de doença
ES2661510T3 (es)	2011-12-15	2018-04-02	Novartis Ag	Uso de inhibidores de la actividad o función de PI3K
WO2013095761A1 (en) *	2011-12-20	2013-06-27	Glaxosmithkline Llc	Imidazopyridine derivatives as pi3 kinase inhibitors
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
JP6078640B2 (ja)	2012-05-15	2017-02-08	ノバルティスアーゲー	Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体
KR20160027217A (ko)	2012-05-23	2016-03-09	에프. 호프만-라 로슈 아게	내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
DK2914296T4 (da)	2012-11-01	2022-01-03	Infinity Pharmaceuticals Inc	Behandling af cancere under anvendelse af PI3-kinase-isoform-modulatorer
EA035391B1 (ru)	2012-11-08	2020-06-05	Ризен Фармасьютикалз Са	Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы
HUE045701T2 (hu)	2013-03-13	2020-01-28	Forma Therapeutics Inc	2-Hidroxi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etán-1-on származékok és rokon vegyületek mint zsírsav szintáz (FASN) inhibitorok, rák kezelésére
WO2014151386A1 (en)	2013-03-15	2014-09-25	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CN103242246A (zh) *	2013-05-21	2013-08-14	苏州科捷生物医药有限公司	3-位取代的n-甲基哌嗪的合成方法
WO2014194254A1 (en)	2013-05-30	2014-12-04	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
ES2900806T3 (es)	2013-10-04	2022-03-18	Infinity Pharmaceuticals Inc	Compuestos heterocíclicos y usos de los mismos
US20160244452A1 (en)	2013-10-21	2016-08-25	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
EP3080101A1 (en)	2013-12-10	2016-10-19	Cleave Biosciences, Inc.	Monocyclic pyrimidine/pyridine compounds as inhibitors of p97 complex
EP3097092B1 (en)	2014-01-20	2020-08-26	Cleave Biosciences, Inc.	Fused pyrimidines as inhibitors of p97 complex
SG10201808053XA (en)	2014-03-19	2018-10-30	Infinity Pharmaceuticals Inc	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015168079A1 (en)	2014-04-29	2015-11-05	Infinity Pharmaceuticals, Inc.	Pyrimidine or pyridine derivatives useful as pi3k inhibitors
EP2974729A1 (en)	2014-07-17	2016-01-20	Abivax	Quinoline derivatives for use in the treatment of inflammatory diseases
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
LT3277682T (lt)	2015-03-30	2019-06-25	Daiichi Sankyo Company, Limited	6-morfolinil-2-pirazolil-9h-purino dariniai ir jų panaudojimas kaip pi3k inhibitorių
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
JP6980649B2 (ja)	2015-09-14	2021-12-15	インフィニティーファーマシューティカルズ，インコーポレイテッド	イソキノリノン誘導体の固体形態、それを製造する方法、それを含む組成物、及びそれを使用する方法
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
TW201825465A (zh)	2016-09-23	2018-07-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh)	2016-09-23	2018-04-16	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh)	2016-09-23	2018-05-01	美商基利科學股份有限公司	磷脂醯肌醇3-激酶抑制劑
US10822336B2 (en)	2016-09-29	2020-11-03	Daiichi Sankyo Company, Limited	Crystals of [2-(1-methyl-1H-pyrazol-4-yl)-6(morpholin-4-yl)-9H-purin-8-yl][4-(morpholin-4-yl)piperidin-1-yl]methanone and pharmaceutically acceptable salt thereof
KR102399639B1 (ko)	2016-12-02	2022-05-18	다이이찌 산쿄 가부시키가이샤	신규 엔도-β-N-아세틸글루코사미니다아제
CN107163061A (zh) *	2017-04-14	2017-09-15	江西科技师范大学	含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
AU2018271862B2 (en)	2017-05-23	2022-12-15	Mei Pharma, Inc.	Combination therapy
CN109111447A (zh)	2017-06-23	2019-01-01	中国科学院上海药物研究所	7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
US11351176B2 (en)	2017-08-14	2022-06-07	Mei Pharma, Inc.	Combination therapy
US20220041588A1 (en) *	2018-09-27	2022-02-10	Fochon Pharmaceuticals, Ltd.	Substituted imidazo[1,2-a]pyridine and [1,2,4]triazolo[1,5-a]pyridine compounds as ret kinase inhibitors
TWI767148B (zh)	2018-10-10	2022-06-11	美商弗瑪治療公司	抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en)	2018-10-29	2020-05-07	Forma Therapeutics, Inc.	SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
KR102117083B1 (ko)	2018-10-30	2020-05-29	계명대학교 산학협력단	벤조헤테로사이클 화합물 및 이를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물
CN111253390B (zh) *	2018-11-30	2023-10-03	四川科伦博泰生物医药股份有限公司	并环化合物、其制备方法及用途
EP3669873A1 (en)	2018-12-20	2020-06-24	Abivax	Quinoline derivatives for use ine the traeatment of inflammation diseases
CN110577515B (zh) *	2019-09-02	2022-05-17	南通大学	一种4-(氮杂环丁烷-3-基)-1-甲基哌嗪-2-酮二盐酸盐的合成方法
CN112920199B (zh) *	2020-06-02	2023-02-03	四川大学	一种哌嗪酮取代物或其衍生物及其制备方法和应用、药物组合物
US20240150358A1 (en) *	2020-06-03	2024-05-09	Kineta, Inc.	Purines and methods of their use
US20240050432A1 (en)	2020-12-08	2024-02-15	Infinity Pharmaceuticals, Inc.	Eganelisib for use in the treatment of pd-l1 negative cancer
WO2022268025A1 (zh) *	2021-06-22	2022-12-29	成都苑东生物制药股份有限公司	Atr抑制剂及其用途
WO2023020604A1 (zh) *	2021-08-20	2023-02-23	南京大美生物制药有限公司	一种五元含氮杂环并杂芳基类衍生物及其用途
WO2023096850A1 (en) *	2021-11-24	2023-06-01	Geode Therapeutics Inc.	Phosphoinositide 3 kinase gamma inhibitors and compositions and methods thereof
WO2023107552A2 (en) *	2021-12-08	2023-06-15	Kineta, Inc.	Purines and methods of their use
CN116262758B (zh) *	2021-12-15	2025-02-28	上海博悦生物科技有限公司	7-甲基噻唑并[5,4-d]嘧啶类化合物、制备方法及其用途
CN116730913A (zh) *	2023-06-12	2023-09-12	上海凌凯医药科技有限公司	一种吡啶α位引入带有酰基保护的氨基的方法
WO2025212599A1 (en) *	2024-04-03	2025-10-09	Gilead Sciences, Inc.	PI3Kalpha INHIBITORS AND USES THEREOF
WO2025234404A1 (ja) *	2024-05-07	2025-11-13	全薬工業株式会社	ピリミジン含有縮合環化合物及びその用途
CN119390697B (zh) *	2024-10-28	2025-08-08	西安医学院	一种杂环化合物及其制备方法和用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3016378A (en)	1959-07-01	1962-01-09	Thomae Gmbh Dr K	Amino-substituted purine derivatives
DE1470356A1 (de)	1964-01-15	1970-04-30	Thomae Gmbh Dr K	Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr)	1969-08-08	1971-02-08	Thomae Gmbh Dr K	Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
BE759493A (fr)	1969-11-26	1971-05-25	Thomae Gmbh Dr K	Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en)	1970-01-28	1973-10-02	Boehringer Sohn Ingelheim	2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr)	1971-05-04	1978-01-15	Thomae Gmbh Dr K	Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
AT321295B (de)	1971-11-11	1975-03-25	Thomae Gmbh Dr K	Verfahren zur Herstellung von neuen Thiazolo[5,4-d]-pyrimidin-Derivaten und ihren Salzen
BE791242A (fr)	1971-11-11	1973-05-10	Thomae Gmbh Dr K	Nouvelles thiazolo(5,4-d)pyrimidines
CH592668A5 (pt)	1973-10-02	1977-10-31	Delalande Sa
GB1570494A (en)	1975-11-28	1980-07-02	Ici Ltd	Thienopyrimidine derivatives and their use as pesticides
US4196207A (en)	1977-05-23	1980-04-01	Ici Australia Limited	Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JPS60260579A (ja)	1984-01-13	1985-12-23	Yoshitomi Pharmaceut Ind Ltd	プリン誘導体
US5332744A (en)	1989-05-30	1994-07-26	Merck & Co., Inc.	Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5075305A (en)	1991-03-18	1991-12-24	Warner-Lambert Company	Compound, composition and use
AU3262593A (en)	1992-01-11	1993-08-03	Schering Agrochemicals Limited	Biheterocyclic fungicidal compounds
US5543523A (en)	1994-11-15	1996-08-06	Regents Of The University Of Minnesota	Method and intermediates for the synthesis of korupensamines
KR100446363B1 (ko)	1997-11-11	2004-09-01	화이자 프로덕츠 인코포레이티드	항암제로 유용한 티에노피리미딘 및 티에노피리딘 유도체
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6232320B1 (en)	1998-06-04	2001-05-15	Abbott Laboratories	Cell adhesion-inhibiting antiinflammatory compounds
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
EP1409125B1 (en)	2001-07-12	2016-04-20	Reaxa Limited	Microencapsulated catalyst, methods of preparation and methods of use thereof
EP1427413A2 (en)	2001-09-13	2004-06-16	Synta Pharmaceuticals Corporation	2-aroylimidazole compounds for treating cancer
US20030139427A1 (en)	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
JP4768265B2 (ja)	2002-10-15	2011-09-07	シンタファーマシューティカルズコーポレーション	新規化合物
ES2217956B1 (es)	2003-01-23	2006-04-01	Almirall Prodesfarma, S.A.	Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
WO2005000404A2 (en)	2003-05-29	2005-01-06	Synta Pharmaceuticals, Corp.	Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
JP4862654B2 (ja)	2004-10-08	2012-01-25	アステラス製薬株式会社	芳香環縮合ピリミジン誘導体
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
GB0508471D0 (en)	2005-04-26	2005-06-01	Celltech R&D Ltd	Therapeutic agents
AU2006278627B2 (en)	2005-08-08	2011-08-18	Janssen Pharmaceutica, N.V.	Thiazolopyrimidine kinase inhibitors
CN103524392B (zh)	2005-10-07	2018-06-01	埃克塞利希斯股份有限公司	作为用于治疗增生性疾病的mek 抑制剂的吖丁啶
GB2431156A (en) *	2005-10-11	2007-04-18	Piramed Ltd	1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
CN101384586A (zh) *	2006-02-14	2009-03-11	诺华公司	Pi-3激酶抑制剂及其应用方法
CN101511840A (zh)	2006-04-26	2009-08-19	吉宁特有限公司	磷酸肌醇3-激酶抑制剂化合物及其使用方法
WO2007129161A2 (en)	2006-04-26	2007-11-15	F. Hoffmann-La Roche Ag	Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
BRPI0710866A2 (pt)	2006-04-26	2012-08-14	Hoffmann La Roche	compostos farmacÊuticos
PT2041139E (pt) *	2006-04-26	2012-01-13	Hoffmann La Roche	Compostos farmacêuticos
GB0608820D0 (en)	2006-05-04	2006-06-14	Piramed Ltd	Pharmaceutical compounds
US7919490B2 (en)	2006-10-04	2011-04-05	Wyeth Llc	6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
ES2544082T3 (es)	2006-12-07	2015-08-27	F. Hoffmann-La Roche Ag	Compuestos inhibidores de fosfoinosítido 3-quinasa y métodos de uso
KR101507182B1 (ko)	2006-12-07	2015-03-30	제넨테크, 인크.	포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
US20080233127A1 (en) *	2007-03-21	2008-09-25	Wyeth	Imidazolopyrimidine analogs and their use as pi3 kinase and mtor inhibitors
WO2008152394A1 (en)	2007-06-12	2008-12-18	F.Hoffmann-La Roche Ag	Pharmaceutical compounds
EP2158207B1 (en) *	2007-06-12	2011-05-25	F. Hoffmann-La Roche AG	Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase
CA2704711C (en)	2007-09-24	2016-07-05	Genentech, Inc.	Thiazolopyrimidine p13k inhibitor compounds and methods of use
JP2011500702A (ja) *	2007-10-16	2011-01-06	ワイス・エルエルシー	チエノピリミジンおよびピラゾロピリミジン化合物ならびにｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのその使用
CN101835779B (zh)	2007-10-26	2014-01-29	霍夫曼-拉罗奇有限公司	作为pi3激酶抑制剂的嘌呤衍生物
GB0721095D0 (en)	2007-10-26	2007-12-05	Piramed Ltd	Pharmaceutical compounds
US8158624B2 (en)	2008-05-30	2012-04-17	Genetech, Inc.	Purine PI3K inhibitor compounds and methods of use

2010
- 2010-05-26 EP EP10720979A patent/EP2435438A1/en not_active Withdrawn
- 2010-05-26 WO PCT/US2010/036199 patent/WO2010138589A1/en not_active Ceased
- 2010-05-26 MX MX2011012520A patent/MX2011012520A/es active IP Right Grant
- 2010-05-26 JP JP2012513210A patent/JP5781066B2/ja not_active Expired - Fee Related
- 2010-05-26 CA CA2761445A patent/CA2761445A1/en not_active Abandoned
- 2010-05-26 AU AU2010254161A patent/AU2010254161A1/en not_active Abandoned
- 2010-05-26 SG SG2011073335A patent/SG175708A1/en unknown
- 2010-05-26 US US12/787,613 patent/US8173650B2/en not_active Expired - Fee Related
- 2010-05-26 BR BRPI1009022A patent/BRPI1009022A2/pt not_active IP Right Cessation
- 2010-05-26 KR KR1020117031050A patent/KR20130026364A/ko not_active Ceased
- 2010-05-26 CN CN201080033023.2A patent/CN102459272B/zh not_active Expired - Fee Related
2011
- 2011-10-06 IL IL215580A patent/IL215580A0/en unknown
2012
- 2012-03-22 US US13/427,081 patent/US8394796B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8173650B2 (en)	2012-05-08
SG175708A1 (en)	2011-12-29
JP5781066B2 (ja)	2015-09-16
IL215580A0 (en)	2011-12-29
CN102459272A (zh)	2012-05-16
CA2761445A1 (en)	2010-12-02
CN102459272B (zh)	2014-08-06
US20120178736A1 (en)	2012-07-12
WO2010138589A1 (en)	2010-12-02
MX2011012520A (es)	2011-12-12
US20100305096A1 (en)	2010-12-02
AU2010254161A1 (en)	2011-11-10
JP2012528179A (ja)	2012-11-12
US8394796B2 (en)	2013-03-12
KR20130026364A (ko)	2013-03-13
EP2435438A1 (en)	2012-04-04

Publication	Publication Date	Title
BRPI1009022A2 (pt)	2016-03-08	"composto, composição farmacêutica, processo para produzir uma composição farmacêutica, uso de um composto, método para tratamento de uma doença ou transtorno e kit"
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0715531A2 (pt)	2014-06-24	Composto, composição farmacêutica, método para o tratamento de uma enfermidade e/ou distúrbio metabólico, processo para a preparação de compostos e uso do composto
BRPI0812851A2 (pt)	2014-09-30	Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto
BR112014010439A2 (pt)	2017-04-18	compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0911685A2 (pt)	2015-10-13	composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit
BRPI0819799A2 (pt)	2015-05-26	Composto, intermediário, uso de um composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença
BR122020011920A2 (pt)	2020-08-25	composto, composição farmacêutica, método para tratar uma doença, uso de um composto, e processos para a preparação de um composto, e para a fabricação de um composto
BRPI0917458A2 (pt)	2015-12-01	composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
BRPI0913585A2 (pt)	2015-10-27	composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0921687A2 (pt)	2015-08-18	Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BRPI0812521A2 (pt)	2015-06-23	Composto, composição farmacêutica, método para o tratamento de doença em um mamífero, processo para a preparação de um composto, e, uso de um composto
BRPI0907977A2 (pt)	2015-08-04	Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BR112012028530A2 (pt)	2017-12-19	composto, composição farmacêutica e seu processo de preparação e método para o tratamento de uma doença ou transtorno
BRPI0811275A2 (pt)	2014-12-23	Composto, processo para a preparação do mesmo, composição farmacêutica, uso de composto, e, método para tratar doença
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0816553A2 (pt)	2017-07-18	"composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0906805A2 (pt)	2015-07-14	Composto, processo para preparar o enanciômero puro, composição farmacêutica, uso do enanciômero puro, métodos para prevenir ou tratar doença em um animal de sangue quente, e, combinação
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0820578A2 (pt)	2015-06-16	Vírus da varíola, processo para preparar um vírus da varíola, composição, uso de um vírus da varíola ou de uma composição, e, método para tratar doenças
BRPI0917705A2 (pt)	2016-02-16	composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto

Legal Events

Date	Code	Title	Description
2016-09-13	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 6A ANUIDADE.
2017-01-10	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.